Table 2.

CAR T cell clinical trials with reported incidences of CRS and neurotoxicity.

	CAR construct	CRS (%)	sCRS (%)	ICANS (%)	sICANS (%)
ALL
Grupp et al. (19)	CD19 4-1BBt	–	13A	–	9A
Park et al. (20)	CD19 28z	85M	26	44C	42
Maude et al. (9)	CD19 4-1BBt	77P	46	40C	13
Fry et al. (21)	CD22 4-1BB	76C*	0	25C	0
Gardner et al. (22)	CD19 4-1BB	93C*	23	44C*	21
Turtle et al. (23)	CD19 4-1BB	83C	23	50C*	50
Lee et al. (24)	CD19 28z	75C*	30	30C	5
Maude et al. (25)	CD19 4-1BBt	88C*	27	43C	–
NHL
Brudno et al. (26)	hCD19 28z	80A	10	20C	5
Pasquini et al. (4)	CD19 28za	83A	14	61A	–
Jaglowski et al. (3)	CD19 4-1BBt	–	4A	–	4A
Kochenderfer et al. (27)	CD19 28z	–	18C	–	55C
Neelapu et al. (10)	CD19 28za	93L	13	64C	28
Schuster et al. (28)	CD19 4-1BBt	57P	18	39C	11
Turtle et al. (29)	CD19 4-1BB	63C*	13	28C*	28
CLL
Fraietta et al. (30)#	CD19 4-1BB	69C	38	6C	0
Turtle et al. (31)	CD19 4-1BB	83C*	8	33C*	25
Hodgkin Lymphoma
Ramos et al. (32)	CD30 28z	0C	0	0C	0
Wang et al. (33)	CD30 4-1BB	0C	0	0C	0
Multiple Myeloma
Raje et al. (34)	BCMA 4-1BB	76L	6	42C	3
Cohen et al. (35)	BCMA 4-1BB	88P	32	32C	12
Brudno et al. (36)	BCMA 28z	93C	29	–	14C
Zhao et al. (37)	BCMA 4-1BB	90L	7	2C	0
Ali et al. (38)	BCMA 28z	50C	25	25C	8
AML
Ritchie et al. (39)	LEY 28z	25C	0	0C	0

sCRS, severe CRS (grade ≥ 3). sICANS, severe ICANS (grade ≥ 3). CRS and ICANS grading systems used by each trial is denoted by superscripts as follows (15): A, ASTCT criteria; C, CTCAE criteria; L, Lee criteria; P, PENN/CHOP criteria; M, MSKCC criteria; *, modified, please refer to the individual publication for details. -, not reported. ^#, toxicities only reported for responders.